The study is a randomised, double-blinded, placebo-controlled, crossover study enrolling 10 healthy male participants. Each participant will undergo four separate study days in randomised order. Each study day encompasses a continous 90-minute i.v. infusion with either placebo, glucose-dependent insulinotropic polypeptide (GIP), alanine or GIP + alanine. The primary objective of the study is to find out whether intravenous administration of the naturally occuring gut hormone GIP and the amino acid alanine, separately and combined, results in additive or synergistic glucagonotropic effects during euglycaemic conditions in healthy participants. Secondary objectives are to disclose the effect of the abovementioned interventions on insulin secretion and circulating levels of total and individual amino acids.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
10
Intravenous saline during experimental days.
Intravenous GIP administration during experimental days.
Intravenous alanine administration during experimental days.
Intravenous administration of GIP and alanine during experimental days.
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Capital Region, Denmark
RECRUITINGPlasma concentrations of Glucagon
Baseline
Time frame: Timepoint -30 to 90 minutes
Plasma concentrations of Glucagon
Baseline-corrected area under the curve (bsAUC)
Time frame: Timepoint -30 to 90 minutes
Serum concentration of Insulin
Baseline
Time frame: Timepoint -30 to 90 minutes
Serum concentration of Insulin
Baseline-corrected area under the curve (bsAUC).
Time frame: Timepoint -30 to 90 minutes
Serum concentration of C-peptid
Baseline
Time frame: Timepoint -30 to 90 minutes
Serum concentration of C-peptid
Baseline-corrected area under the curve (bsAUC).
Time frame: Timepoint -30 to 90 minutes
Plasma concentration of glucose
Baseline
Time frame: Timepoint -30 to 90 minutes
Plasma concentration of glucose
Baseline-corrected area under the curve (bsAUC).
Time frame: Timepoint -30 to 90 minutes
Plasma concentration of glucose
Peak value
Time frame: Timepoint -30 to 90 minutes
Plasma concentration of GIP
Baseline
Time frame: Timepoint -30 to 90 minutes
Plasma concentration of GIP
Baseline-corrected area under the curve (bsAUC).
Time frame: Timepoint -30 to 90 minutes
Circulating levels of total amino acids
Baseline
Time frame: Timepoint -30 to 90 minutes
Circulating levels of total amino acids
Baseline-corrected area under the curve (bsAUC).
Time frame: Timepoint -30 to 90 minutes
Circulating levels of individual amino acids
Baseline
Time frame: Timepoint -30 to 90 minutes
Circulating levels of individual amino acids
Baseline-corrected area under the curve (bsAUC).
Time frame: Timepoint -30 to 90 minutes
Lipid profile
Baseline
Time frame: Timepoint -30 to 90 minutes
Lipid profile
Baseline-corrected area under the curve (bsAUC).
Time frame: Timepoint -30 to 90 minutes
Circulating levels of CTx
Baseline
Time frame: Timepoint -30 to 90 minutes
Circulating levels of CTx
Baseline-corrected area under the curve (bsAUC).
Time frame: Timepoint -30 to 90 minutes
Circulating levels of P1NP
Baseline
Time frame: Timepoint -30 to 90 minutes
Circulating levels of P1NP
Baseline-corrected area under the curve (bsAUC).
Time frame: Timepoint -30 to 90 minutes
Blood pressure
Baseline
Time frame: Timepoint -30, 0, 30, 60, 90
Blood pressure
Baseline-corrected area under the curve (bsAUC).
Time frame: Timepoint -30, 0, 30, 60, 90
Pulse
Baseline
Time frame: Timepoint -30, 0, 30, 60, 90
Pulse
Baseline-corrected area under the curve (bsAUC).
Time frame: Timepoint -30, 0, 30, 60, 90
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.